Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

Vandana Singh
·1 min read

  • Danaher Corporation (NYSE: DHR) has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc (NYSE: CTLT).

  • According to the sources, the recent moves by the life science firm valued Catalent at a significant premium.

  • It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, Bloomberg reported citing people familiar with the matter.

  • Related: Danaher Says 2022 'Another Great Year,' Delivers Around 10% Core Revenue Growth.

  • Danaher and Catalent deal could be one of the largest transactions this year in a sleepy dealmaking market, with volumes down two-thirds globally, the report added.

  • "As a matter of company policy, Catalent does not comment on market rumors or speculation," the report cited a company spokesperson.

  • Also Read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.

  • Last year, Catalent received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity drug Wegovy.

  • Catalent provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The manufacturer has gained distinction during the pandemic, helping to produce COVID-19 vaccines and treatments in partnership with companies including Moderna Inc (NASDAQ: MRNA), Johnson & Johnson (NYSE: JNJ), and AstraZeneca Plc (NASDAQ: AZN).

  • Price Action: CTLT shares are up 25.74% at $70.48 during the premarket session on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.